The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Galan Lithium
GLN:AU
International Graphite
IG6:AU
Cardiex Limited
CDX:AU
CVD Equipment Corporation
CVV:US
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
biOasis Technologies CEO Discusses Blood Brain Barrier Technology
Nov. 20, 2014 02:37PM PST
Life Science Investing NewsMidas Letter released a podcast interview with Rob Hutchison, CEO and chairman of biOasis Technologies Inc. (TSXV:BTI,OTCQX:BIOAF).
Midas Letter released a podcast interview with Rob Hutchison, CEO and chairman of biOasis Technologies Inc. (TSXV:BTI,OTCQX:BIOAF). In it, he discusses the company’s blood brain barrier technology, which “reliably delivers therapeutic compounds beyond the Blood Brain Barrier in mice so far.”
Hutchison states:
From our perspective, biOasis has over the last number of years … actually completed all of the ground-level experimental work that was necessary to advance this technology forward. It’s now been vetted by independent third parties, including industry itself — in other words, large pharma companies have evaluated the technology. So I think it provides an opportunity for immediate potential opportunities for shareholders and investors.
Click here to listen to the podcast at the Midas Letter site.
Outlook Reports
Featured Stocks
Browse Companies
MARKETS
COMMODITIES
| Commodities | |||
|---|---|---|---|
| Gold | 2321.38 | +5.08 | |
| Silver | 27.31 | +0.13 | |
| Copper | 4.51 | +0.02 | |
| Oil | 82.86 | +0.05 | |
| Heating Oil | 2.57 | +0.01 | |
| Natural Gas | 1.67 | +0.01 | |
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.